4) 13.1 (2.5) 50 Total (N) 86 84 84 aTotal intake www.selleckchem.com/products/lazertinib-yh25448-gns-1480.html differed between categories of 25-OHD (ANOVA; p = 0.03) bDistribution of D2 users differed between categories (chi square; p = 0.001) Tibia BMC, CSA and BMD Bone measurements were successful in 68 of subjects (78%) at the 14-month visit. Determinants of bone variables were gender, birth weight Z-score, walking age, duration of exclusive breastfeeding and S-25-OHD at 14 months. At the 14-month visit, boys had a higher BMC, ΔBMC and BMD than girls (independent samples t-test; p = 0.002, p = 0.002 and p = 0.02, respectively).

Birth weight Z-score correlated strongly with BMC selleck chemical and CSA at 14 months selleck chemicals (r = 0.507, p < 0.001 and r = 0.368, p = 0.004). Similarly, walking age was inversely associated with BMC, CSA and S-25-OHD at 14 months (r = −0.545, p < 0.001, r = −0.433, p < 0.001, and r = −0.194, p = 0.083, respectively). The duration of exclusive breastfeeding correlated negatively

with BMC, ΔBMC, CSA and ΔCSA (r varying from −0.377 to −0.428, p = 0.002). S-25-OHD at the 14-month visit was only modestly related to BMD and ΔBMD (r = −0.230, p = 0.08 and r = −0.142, p = 0.250), but was included in the model as well. The development of BMC from baseline to 14 months differed between the groups (repeated-measures multivariate analysis of variance [MANOVA]; p = 0.023) (Fig. 2a) due to greater baseline BMC in High D. However, the total BMC gain (∆BMC = BMC14 month − BMCbaseline) during the first year was 0.062 (SEM = 0.029) g/cm greater in Low D (MANOVA; p = 0.032); consequently,

no difference was observed in BMC between the groups at the 14-month visit. TB CSA from baseline to the 14-month visit was significantly higher in High D than in Low D (repeated MANOVA; p = 0.004) (Fig. 2b) due to the higher baseline CSA in High D. SDHB ∆CSA did not differ between the groups. Thus, a trend to higher CSA at 14 months by 14.6 (SEM = 7.8) mm2 (MANOVA; p = 0.068) remained in High D. There was no difference between the groups in BMD during the 14 months (Fig. 2c) or in ΔBMD. The observed decrease in BMD is a consequence of a greater increment in CSA compared with the gain in BMC (69% vs. 18%). Fig. 2 BMC, CSA and BMD in study groups from baseline to 14 months. Increase in BMC from baseline to 14 months differed between the groups (repeated-measures MANOVA; p = 0.023) (a) due to higher baseline BMC in High D. No difference was observed in BMC between the groups at the 14-month visit. TB CSA from baseline to 14 months was significantly higher in High D than in Low D (repeated-measures MANOVA; p = 0.004) (b) due to the higher baseline CSA in High D. At 14 months, CSA remained 14.6 (SEM = 7.8) mm2 (MANOVA; p = 0.068) higher in High D. There was no difference between the groups in BMD during the 14 months (c) or in ΔBMD.